Biotoscana Investments

Biotoscana Investments (GBT) was a leading biopharmaceutical group in Latin America, specializing in the licensing, manufacturing, and commercialization of advanced specialty pharmaceutical products. The company focused on high-unmet-need therapeutic areas including oncology, hematology, infectious diseases, and rare diseases across major Latin American markets such as Brazil, Colombia, and Argentina. GBT operated through a business model centered on strategic partnerships with global pharmaceutical companies to bring innovative treatments to the region. Its portfolio included significant brands such as Cresemba, Halaven, and Lenvima, managed through its subsidiaries United Medical, Laboratorios Biotoscana, and LKM. In 2019, the company was acquired by the Canadian specialty pharma firm Knight Therapeutics, which integrated GBT's extensive regional infrastructure into its global operations.